BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →

Loading MRK charts…

Search ticker or company⌘K

MRK

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

MRK · Merck & Co., Inc. fundamentals · vpside

vpside

⌘K

MRKMarket cap $369B/Last filing 10-Q, Q2 FY26 · 7 Aug 2026/MRKMarket cap $369B/Last filing 10-Q, Q2 FY26 · 7 Aug 2026/MRKMarket cap $369B/Last filing 10-Q, Q2 FY26 · 7 Aug 2026/MRKMarket cap $369B/Last filing 10-Q, Q2 FY26 · 7 Aug 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

MRK

Merck & Co., Inc.

NYSE · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$16.61B+5.1% year on year

$20B$10B$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 7 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

73.0%−3.6 pp year on year

80%75%70%65%

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 7 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$6.85B−14.5% year on year

$20B$10B$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 7 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$16.06B+9.1% year on year

$20B$10B$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 7 Aug 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters